{
  "id": 10925498,
  "title": "Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy",
  "url": "https://urgent.news/2026/09/30/satellos-announces-completion-of-enrollment-in-basecamp-phase-2",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-30T11:03:55.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/satellos-announces-completion-of-enrollment-in-basecamp-phase-2-clinical-trial-of-forazapadin-for-duchenne-muscular-dystrophy"
  },
  "original_language": "en",
  "account": null,
  "summary": "Data from BASECAMP expected in Q1 2027 TORONTO, Sept. 30, 2026 (GLOBE NEWSWIRE) — Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced that enrollment has been completed for BASECAMP, the company’s Phase 2 clinical trial evaluating forazapadin for the treatment of […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}